Introduction {#Sec1}
============

MRSA with reduced vancomycin susceptibility phenotype (MRSA-RVS) including heterogeneous vancomycin-intermediate *S*. *aureus* (hVISA) and vancomycin-susceptible *S*. *aureus* (VSSA) with elevated vancomycin MIC (MIC ≥ 1.5 mg/L) have been increasingly reported in the past decade^[@CR1]--[@CR5]^. Although the vancomycin MIC of 1.5--2 mg/L remains in the susceptible range, observational studies in the past few years have demonstrated that infections with MRSA-RVS were significantly associated with treatment failure and poor outcomes when treated with vancomycin^[@CR5]--[@CR8]^. A meta-analysis showed that high vancomycin MIC was significantly associated with treatment failure irrespective of the source of infection or MIC methodology^[@CR9]^. Another systemic review further demonstrated that the hVISA phenotype was associated with increased incidence of treatment failure, though the 30-day mortality was similar for hVISA and VSSA infections^[@CR10]^. These results suggested that the RVS phenotype is an independent factor associated with poor treatment response in patients with MRSA infections.

Intriguingly, it appears that the poor treatment response of patients could not simply be explained by inadequate treatment with vancomycin. Holmes *et al*. demonstrated that RVS phenotype can be significantly associated with increased mortality in patients with methicillin-susceptible *S*. *aureus* bacteremia who were treated with beta-lactams^[@CR11]^. The underlying mechanism of the association between RVS and poor outcome is not clear and may involve a variety of bacterial genetic or phenotypic features other than drug susceptibility. Understanding of the mechanism will help develop strategies against this medically important pathogen. The accessory gene regulator (*agr)* is a well-studied global regulator of *S*. *aureus*, which controls the expression of a wide array of virulence factors and surface proteins. The *agr* locus was frequently mutated and its function is often compromised in *S*. *aureus* with incremental non-susceptibility to vancomycin^[@CR12],[@CR13]^. The study was aimed to identify factors predicting treatment failure and adverse outcomes in patients with bacteremia caused by MRSA with a vancomycin MIC of 2 mg/L, with focus on a variety of bacterial factors including genotypes, hVISA phenotype and *agr* function.

Results {#Sec2}
=======

Patient features and outcomes {#Sec3}
-----------------------------

A total of 147 episodes of bacteremia caused by MRSA with vancomycin MIC of 2 mg/L were identified in 147 patients in this study. The mean ± standard deviation age was 63.5 ± 18.1 years and male gender accounted for 61.2% (90/147) of the cases. Among the147 episodes, 41 (27.9%) episodes were acquired in the community and only 9 (6.12%) episodes occurred in patients without any healthcare-associated risk. Catheter (38.1%) was the most common source of bacteremia. This was followed by pneumonia (23.1%) and skin/soft tissue infections (16.3%). Common comorbidities included renal insufficiency (47.6%), end-stage renal disease requiring dialysis (45.6%), and hypertension (44.9%). Empirical antibiotics with activity against MRSA were administered to 55 (37.4%) cases. Glycopeptides remained to be the most commonly used definitive antimicrobial agent (54.4%, 80/147). Daptomycin was used as the definitive agent in 55(37.4%) of the patients. Sixty-eight patients (46.3%) were treated successfully. The 30-day mortality was 32.0% (47/147) in this cohort. The demographics and clinical features of the 147 patients are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Univariate analysis of clinical parameters associated with treatment failure and 30-day mortality in 147 episodes of bacteremia due to methicillin-resistant *Staphylococcus aureus* (MRSA) with vancomycin MIC of \>1.5 mg/L in a teaching hospital in Taiwan, 2009--2011.FactorTotal\
(n = 147)Treatment response30-day outcomeFailure\
(n = 79)Success\
(n = 68)P valueDied\
(n = 47)Survived\
(n = 100)P valueDemographics and medical history Female gender (%)57 (38.8)30 (38.0)27 (39.7)0.829918 (38.3)39 (39.0)0.9351 Age in years (SD)63.5 (18.1)65.7 (16.5)60.9 (19.5)0.107868.7 (16.2)61.0 (18.5)0.0161Previous *S*. *aureus* infections (%)68 (46.3)41 (51.9)27 (39.7)0.139320 (42.6)48 (48.0)0.5368glycopeptide exposure within 3 mo61 (41.5)38 (48.1)23 (33.8)0.079819 (40.4)42 (42.0)0.8566Community-acquired infections41 (27.9)16 (20.3)25 (36.8)0.02607 (14.9)34 (34.0)0.0160Source of bacteremia (concomitant infections) Catheter-associated (%)56 (38.1)31 (39.2)25 (36.8)0.757920 (42.6)36 (36.0)0.4454 Bone/joint infections (%)19 (12.9)9 (11.4)10 (14.7)0.55051 (2.13)18 (18.0)0.0075 Cardiovascular infections (%)8 (5.44)5 (6.33)3 (4.41)0.7253^\*^2 (4.26)6 (6.00)1.000^\*^ Skin and soft tissue infections (%)24 (16.3)8 (10.1)16 (23.5)0.02845 (10.6)19 (19.0)0.2008 Pneumonia (%)34 (23.1)24 (30.4)10 (14.7)0.024617 (36.2)17 (17.0)0.0101 Intra-abdominal infections (%)1 (0.68)0 (0)1 (1.47)0.4626^\*^0 (0)1 (1.00)1.000^\*^ Urinary tract infections (%)3 (2.04)0 (0)3 (4.41)0.0966^\*^0 (0)3 (3.00)0.5514^\*^ Unknown (%)23 (15.7)13 (16.5)10 (14.7)0.770910 (21.3)13 (13.0)0.1977Comorbidities Charlson index, median (range)5 (0--14)6 (0--14)4 (0--12)0.0027^\#^6 (0--14)4 (0--12)0.0107^\#^ DM without end organ damage (%)21 (14.3)10 (12.7)11 (16.2)0.54335 (10.6)16 (16.0)0.3863 DM with end organ damage (%)37 (25.2)23 (29.1)14 (20.6)0.235010 (21.3)27 (27.0)0.4558 Hypertension (%)66 (44.9)32 (40.5)34 (50.0)0.248617 (36.2)49 (49.0)0.1447 Heart failure (%)26 (17.7)21 (26.6)5 (7.35)0.00239 (19.2)17 (17.0)0.7501 History of myocardial infarction (%)6 (4.08)3 (3.80)3 (4.41)1.000^\*^2 (4.26)4 (4.00)1.000^\*^ Peripheral vascular disease (%)16 (10.9)10 (12.7)6 (8.82)0.45676 (12.8)10 (10.0)0.6155 COPD (%)7 (4.76)5 (6.33)2 (2.94)0.4512^\*^4 (8.51)3 (3.00)0.2105^\*^ Mild hepatic dysfunction (%)9 (6.12)6 (7.59)3 (4.41)0.5056^\*^1 (2.13)8 (8.00)0.2724^\*^ Moderate/severe liver diseases (%)20 (13.6)13 (16.5)7 (10.3)0.277311 (23.4)9 (9.00)0.0175  Renal insufficiency (%)70 (47.6)40 (50.6)30 (44.1)0.430321 (44.7)49 (49.0)0.6248 On dialysis (%)67 (45.6)41 (51.9)26 (38.2)0.097223 (48.9)44 (44.0)0.5752 History of CVA (%)30 (20.4)21 (26.6)9 (13.2)0.045311 (23.4)19 (19.0)0.5366 Hemiplegia (%)25 (17.0)16 (20.3)9 (13.2)0.25887 (14.9)18 (18.0)0.6401 Dementia (%)21 (14.3)12 (15.2)9 (13.2)0.73567 (14.9)14 (14.0)0.8852 Peptic ulcer (%)23 (15.7)15 (19.0)8 (11.8)0.229413 (27.7)10 (10.0)0.0060 Immunosuppressive therapy (%)9 (6.12)8 (10.1)1 (1.47)0.0380^\*^5 (10.6)4 (4.00)0.1453 Organ transplant (%)1 (0.68)0 (0)1 (1.47)0.4626^\*^0 (0)1 (1.00)1.000^\*^ Connective tissue diseases (%)2 (1.36)2 (2.53)0 (0)0.4994^\*^1 (2.13)1 (1.00)0.5387^\*^ Malignant lymphoma/leukemia (%)4 (2.72)3 (3.80)1 (1.47)0.62412 (4.26)2 (2.00)0.5930^\*^ Tumor without metastasis (%)15 (10.2)6 (7.59)9 (13.2)0.26005 (10.6)10 (10.0)1.000^\*^ Metastatic solid tumor (%)20 (13.6)14 (17.7)6 (8.82)0.116712 (25.5)8 (8.00)0.0038 Surgery requiring hospitalization in previous 30 days (%)16 (10.9)8 (10.1)8 (11.8)0.75054 (8.51)12 (12.0)0.5264Condition at disease onset Bacteremia occurring in ICU35 (23.8)22 (27.9)13 (19.1)0.215320 (42.6)15 (15.0)0.0003 Pitt bacteremia score, median (range)2 (0--12)4 (0--12)1 (0--7)\<0.0001^\#^5 (0--12)1 (0--10)\<0.0001^\#^ Laboratory data at bacteremia onset Hemoglobin, g/dL (SD)9.60 (1.74)9.62 (1.83)9.58 (1.65)0.86809.55 (1.61)9.63 (1.81)0.7908 WBC, /μl (SD)13,489 (8138)14,145 (8942)12,756 (7130)0.307915302 (8747)12665 (7197)0.1090 Platelet, /μl (SD)184K (102K)169K (148K)201K (114K)0.0678158K (101K)196K (101K)0.0346 C-reactive protein, mg/L (SD)118 (82)125 (83)111 (114)0.4702142 (117)106 (90)0.0127Managements Use of permanent catheter37 (25.2)23 (29.1)14 (20.6)0.235012 (25.5)25 (25.0)0.9447 Removal of catheter during bacteremia21 (14.3)13 (16.5)8 (11.8)0.41777 (14.9)14 (14.0)0.8852 Empirical use of antibiotics with activity against MRSA55 (37.4)33 (41.8)22 (32.4)0.239319 (40.4)36 (36.0)0.6051 Definite regimen0.26450.0149 Daptomycin55 (37.4)27 (34.2)28 (41.2)13 (27.7)42 (42.0) Glycopeptide80 (54.4)43 (54.4)37 (54.4)26 (55.3)54 (54.0) Others12 (8.16)9 (11.4)3 (4.41)8 (17.0)4 (4.00)^\*^Fisher's exact test.^\#^Wilcoxon test.Abbreviations: CVA, cerebral vascular accident; hVISA, heterogeneous vancomycin-intermediate *Staphylococcus aureus*; VSSA, vancomycin-susceptible *S*. *aureus*; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit;.

Strains characteristics {#Sec4}
-----------------------

SCC*mec* type III and *agr* type 1 were the most common genotypes and identified in 105 (71.4%) isolates and 123 (83.7%) isolates, respectively. Community genotypes, including type IV or V SCC*mec*, were identified in 23 (15.6%) isolates. The hVISA phenotype was detected by GRD E-test method in 37.4% of the isolates. The *agr* function was intact in 106 (72.1%) isolates. The detailed characteristics of all isolates are shown in Table [2](#Tab2){ref-type="table"}.Table 2Univariate analysis of microbiological parameters associated with treatment failure and 30-day mortality in 147 episodes of bacteremia due to MRSA with vancomycin MIC = 2 mg/L in a teaching hospital in Taiwan, 2009--2011.FactorTotal (n = 147)Treatment response30-day outcomeFailure\
(n = 79)Success\
(n = 68)P valueDiedSurvivedP valueResistance to Daptomycin (%)11 (7.48)8 (10.1)3 (4.41)0.18924 (8.51)7 (7.00)0.7448  Fusidic acid (%)11 (7.48)6 (7.59)5 (7.35)0.95773 (6.38)8 (8.00)1.000^\*^ Linezolid (%)0 (0)0 (0)0 (0)...0 (0)0 (0)... TMP-SXT (%)108 (73.5)62 (78.5)46 (67.7)0.138037 (78.7)71 (71.0)0.3226 Teicoplanin (%)2 (1.36)0 (0)2 (2.94)0.21230 (0)2 (2.00)1.000^\*^ Tigecycline (%)5 (3.40)4 (5.06)1 (1.47)0.37353 (6.38)2 (2.00)0.3276 Rifampin (%)38 (25.9)23 (29.1)15 (22.1)0.330016 (34.0)22 (22.0)0.1199hVISA phenotype55 (37.4)38 (48.1)17 (25.0)0.003924 (51.1)31 (31.0)0.0191Delta-hemolysis106 (72.1)55 (69.6)51 (75.0)0.468331 (66.0)75 (75.0)0.2542*Agr* type0.25330.6534 Type 1123 (83.7)69 (87.3)54 (79.4)41 (87.2)82 (82.0) Type 221 (14.3)10 (12.7)11 (16.2)6 (12.8)15 (15.0) Type 42 (1.36)0 (0)2 (2.94)0 (0)2 (2.00) untypable1 (0.68)0 (0)1 (2.94)0 (0)1 (1.00)SCC*mec* type0.00720.2801 II16 (10.9)10 (12.7)6 (8.82)6 (12.8)10 (10.0) III105 (71.4)63 (79.8)42 (61.8)37 (78.7)68 (68.0) IV19 (12.9)6 (7.59)13 (19.1)4 (8.51)15 (15.0) V4 (2.72)0 (0)4 (5.88)0 (0)4 (4.00) untypable3 (2.04)0 (0)3 (4.41)0 (0)3 (3.00)PVL genes1 (0.68)0 (0)1 (1.47)0.4626^\*^0 (0)1 (1.00)1.000^\*\*^Fisher's exact test.

Factors associated with treatment failure {#Sec5}
-----------------------------------------

The bacterial factors including susceptibilities to various antibiotics, *agr* type and *agr* function were not associated with treatment response (Table [2](#Tab2){ref-type="table"}). Univariate analysis disclosed that the hVISA phenotype was more commonly identified in patients with treatment failure compared to those who were treated successfully (48.1% versus 25.0%, *P* = 0.0039). The distributions of SCC*mec* types also differed in patients with different treatment responses (*P* = 0.0072, Table [2](#Tab2){ref-type="table"}). After adjustment for clinical covariates, the only bacterial factor associated with increased incidence of treatment failure was the hVISA phenotype (adjusted odds ratio \[aOR\] 2.420, 95% confidence interval \[CI\] 0.946--6.191) though with marginal significance (*P* = 0.0652). Multivariate analysis revealed that the Charlson index (aOR 1.154, 95% CI 1.009--1.320, *P* = 0.0363) and Pitt bacteremia score (aOR 1.391, 95% CI 1.162--1.666, *P* = 0.0003) were independent clinical factors associated with increased incidence of treatment failure (Table [3](#Tab3){ref-type="table"}).Table 3Multivariate analysis of factors associated with treatment failure and 30-day mortality in patients with bacteremia due to MRSA with vancomycin MIC of 2 mg/L.FactorTreatment failure30-day mortalityaOR (95% CI)P valueaOR (95% CI)P valueAge------1.030 (0.999--1.062)0.0573Community-acquired infections0.762 (0.298--1.946)0.56942.324 (0.646--83.61)0.1969Bone/joint infections-----4.834 (0.393--59.438)0.2184Skin and soft tissue infections0.417 (0.136--1.280)0.1262------Pneumonia1.260 (0.435--3.650)0.67001.436 (0.482--4.277)0.5159Charlson index1.154 (1.009--1.320)0.03631.108 (0.951--1.290)0.1873Bacteremia occurring in ICU------2.227 (0.703--7.055)0.1736Pitt bacteremia score1.391 (1.162--1.666)0.00031.298 (1.087--1.549)0.0040Platelet------0.996 (0.991--1.002)0.2162C-reactive protein------1.007 (1.001--1.013)0.0195Definite regimen  daptomycin------0.128 (0.022--0.746)0.0286  glycopeptide------0.238 (0.046--1.246)0.4597  others------Referent---SCC*mec*  Type IIReferent---------  Type III1.065 (0.278--4.075)0.9412------  Type IV1.082 (0.199--5.879)0.9410------  Type V---0.9676------  Non-typable---0.9716------hVISA phenotype2.420 (0.946--6.191)0.06521.698 (0.623--4.631)0.3011

Factors associated with 30-day mortality {#Sec6}
----------------------------------------

Multivariate analysis disclosed that the Pitt bacteremia score and C-reactive protein value at disease onset were independent factors associated with increased incidence of 30-day mortality (aOR 1.298, *P* = 0.0040 and aOR 1.007, *P* = 0.0195, respectively). The use of daptomycin as definitive antimicrobial therapy was independently associated with decreased incidence of 30-day mortality (aOR 0.128, 95% CI 0.022--0.746, *P* = 0.0286). There was no association between bacterial factors and 30-day mortality in this cohort.

Discussion {#Sec7}
==========

The significance of hVISA phenotype on treatment response and patient outcomes had been addressed in previous studies involving bacteremic patients^[@CR3],[@CR7],[@CR13]--[@CR15]^. Data from these studies suggested that the patients with hVISA bacteremia might have higher treatment failure rates compared to those with VSSA bacteremia, The incidence of adverse outcomes were however similar for these infections. In one prospective study Horne *et al*. reported that there is no significant difference in the cure rates of hVISA and VISA infections compared to VSSA infections^[@CR8]^. The authors concluded that the laboratory identification of the MRSA-RVS might be of limited value and might be reserved for isolates from patients who are failing appropriate anti-MRSA therapy. However, a meta-analysis by van Hal *et al*. found out that the hVISA phenotype was associated with a 2.37-fold increased incidence of treatment failure. There was no association between hVISA and 30-day mortality^[@CR10]^. Consistent with the observation by van Hal *et al*., results from our study showed that hVISA phenotype was associated with 2.42 folds increased risk of treatment failure. Unfortunately, the difference was of borderline significance which was most likely owing to relative small number of cases in both groups. Together, the difference in patient populations, methods used in the identification of hVISA phenotype (i.e. PAP-AUC, macromethod E-test and GRD E-test), and heterogeneity between patients infected with hVISA and VSSA may be factors responsible for the conflicting results.

It has been shown that MRSA with high vancomycin MIC (i.e. MIC = 2 g/L) was a factor significantly associated with poor outcome in MRSA bacteremic patients^[@CR16]^. In the current study, in addition to the hVISA phenotype, we failed to identify any bacterial parameters such as antibiotic susceptibilities, SCC*mec* types, *agr* type and *agr* function (δ-hemolysis) that can predict the treatment failure and 30-day mortality when the clinical covariates were adequately controlled. Our data indicated that the clinical condition of the affected patients, particularly the comorbidity and severity at disease onset, remained to be the most critical factor predicting the unfavorable outcomes. This findings supports the current MRSA guideline which stated that the patient's clinical response should be the primary consideration, irrespective of the MIC^[@CR17]^.

It was interesting to note that the use of daptomycin as the definitive regimen was associated with decreased incidence of 30-mortality in this MRSA bacteremia cohort. This observation was in agreement with the results in a recent MRSA bacteremia cohort study which demonstrated a decrease 30-day mortality and persistent bacteremia in patients on early use of daptomycin^[@CR18]^. However, this observation should be interpreted with caution since our study was not designed to address the efficacy of different therapeutic regimen on MRSA bacteremia. The significance of the role of daptomycin in decreased 30-day mortality may be due to other factors that were not considered in this study. For instance, daptomycin was usually used as an alternative agent to glycopeptide in MRSA bacteremic patients. It was likely that those survived 30 days after disease onset might have greater chance of receiving daptomycin treatment. Nevertheless, given the high incidence of case fatality and the potential benefit of this agent in reducing mortality, the early use of antimicrobial agents alternative to glycopeptides should be seriously considered in those with multiple comorbidity and severe infections at disease onset (i.e. high Pitt bacteremia score and CRP).

There were limitations of the study. Firstly, we found out that there was a huge heterogeneity of clinical parameters between the two groups of patients. Heterogeneity of patient characteristics, thought having taken into consideration and adjusted by multivariate logistic regression method, might still exist and potentially skew our findings. A prospective randomized control study with sufficient number of participants will be the ultimate way to clarify the issue addressed in this study. Secondly, the sample size of the study was relative small which might not be able to precisely estimate the impact of certain clinical or bacterial parameters.

In conclusion, bacteremia due to MRSA with high vancomycin MIC is associated with extremely high incidences of treatment failure and adverse outcomes. Our data indicated that the underlying conditions, severity of infection at disease onset and antibiotic regimen remained the most critical factors predicting the patients' outcomes. Our data also suggested that the hVISA phenotype was the only potential factor predicting treatment failure in this population. Based on these findings, we agree that detection of the hVISA phenotype might of clinical relevance and routine laboratory detection might be considered^[@CR8],[@CR19]^.

Methods {#Sec8}
=======

Ethic statements {#Sec9}
----------------

This study was approved by the institutional review boards (IRB) of Chang Gung Memorial Hospital at Linkou (GMH-Linkou). All experimental protocols were performed in accordance with the guidelines and regulations of the IRB of CGMH. A waiver of consent was granted given the retrospective nature of the project and anonymous analysis of the clinical information.

Study design {#Sec10}
------------

The study was conducted in a university-affiliated teaching hospital (CGMH-Linkou) in northern Taiwan from August 2009 to July 2012. The hospital is a 3,715-bed medical center and provided both primary and tertiary healthcare. It consists of 13 disease-oriented departments, including 26 intensive care units (ICUs) and 73 ordinary wards. A central microbiology laboratory was responsible for processing all clinical specimens. From August 01 2009, the microbiology laboratory began to report the vancomycin MICs values for invasive *S*. *aureus* isolates (from sterile sites, i.e. blood). The MICs were determined by the E-test method (BioMerieux, France). The *S*. *aureus* isolates were stored at −80 °C after their isolation and were accompanied by an electronic record containing the information of the isolates and the chart number of patients. We reviewed the clinical information of patients with MRSA bacteremia with a vancomycin MIC = 2 mg/L.

Demographics and anthropometric variables of subjects {#Sec11}
-----------------------------------------------------

Only the initial episodes of bacteremia during the study period was included for analysis to preserve the independence of observations. Positive blood cultures obtained from patients without consistent or persistent features of systemic infections were considered to have been either contaminated or transient bacteremia. Data for such patients were excluded from analysis.

A standardized data collection form was used to collect the medical information needed in this study (Table [1](#Tab1){ref-type="table"}). We identified the possible sources of bacteremia (concomitant infections), comorbid illnesses, concurrent blood isolates of other bacterial species, clinical condition within 48 hours or on the day of onset of bacteremia, laboratory and image findings, ICU stay, empiric and definite antimicrobial regimens and a variety of unfavorable outcomes. Renal insufficiency was defined as a serum creatinine level ≥ 1.4 mg/dL without the requirement of hemodialysis. The sources of bacteremia were identified by reviewing the medical records, radiologic studies, surgical findings and microbiological records of the patients. The Charlson weighted index of comorbidity (WIC) and Pitt bacteremia score were calculated and used as parameters to control for comorbidity and severity of illness at the onset of bacteremia during the analysis of risks associated with treatment failure and 30-day mortality.

Appropriate definitive antimicrobial treatment was defined as antibiotics active against the offending pathogens started within 48 hours of onset of bacteremia and used for at least 3 days. Adjunctive therapy was defined as concurrent surgical intervention or palliative drainage. Treatment failure was defined as inadequate response to therapy, such as the development of resistance to glycopeptide; worsening, recurrent or new onset of signs and symptoms requiring a change of antibiotic regimen; or a positive blood culture for MRSA at the end of therapy. Mortality occurring within 7 days of *S*. *aureus* bacteremia was defined as bacteremia-attributed mortality if there was no other identified cause for death. The 30-day mortality was defined as any cause of death within 30 days of MRSA bacteremia onset.

Determination of hVISA phenotype {#Sec12}
--------------------------------

Etest GRD (bioMérieux, Marcy-l'Etoile, France) was used to determine the hVISA phenotype and performed according to manufacturer's instructions^[@CR20]^. Briefly, a bacterial suspension at a 0.5 McFarland standard was inoculated onto a MHA plate containing 5% sheep blood (BBL; Becton Dickinson, Cockeysville, MD) and incubated at 35 °C. The zone of inhibition was read at 24 and 48 h after incubation. An isolate was considered hVISA if the Etest GRD strip result was ≥8 mg/L for vancomycin or teicoplanin.

δ-Hemolysin production {#Sec13}
----------------------

Delta-hemolysin production is indicative of intact *agr* function. This was measured according to the procedure described elsewhere^[@CR19]^. Briefly, the *S*. *aureus* isolates were streaked perpendicularly to RN4220 on Columbia agar plates (Oxoid, Cambridge, UK) with 5% sheep blood and incubated at 37 °C in 5% CO~2~ overnight. Synergistic hemolysis within the *β*-hemolysin zone produced by RN4220 was evaluated. The presence of synergistic hemolysis indicates the production of δ-hemolysin. ATCC 25923 and Mu50 were used as positive and negative controls, respectively, for the production of δ-hemolysin.

Genotyping of MRSA strains {#Sec14}
--------------------------

Staphylococcal cassette chromosome *mec* element (SCC*mec*) typing of MRSA isolates was performed using a multiplex PCR strategy described in a previous study^[@CR14]^. The control strains for SCC*mec* types I, II, III, IVa, and V~T~ were *S*. *aureus* NCTC10442, N315, 85/2082, JCSC4744 and TSGH-17, respectively. SCC*mec* typing was determined by using a particular primer described elsewhere^[@CR21]^. The presence of Panton-Valentine leukocidin (PVL) genes was determined in all *S*. *aureus* isolates by a PCR technique described by Lina *et al*.^[@CR22]^. The *agr* type was determined as previously described^[@CR23]^. The *agr* sequences were amplified with the following primers, Pan (5′-ATGCACATGGTGCACATGC-3′), *agr*1 (5′-GTCACAAGTACTATAAGCTGCGAT-3′), *agr*2 (5′-TATTAC TAATTGAAA AGTGGCCATAGC-3′), *agr*3 (5′-GTAATGTAATAGCTT GTATAATAATA CCCAG-3′) and *agr*4 (5′-CGATAATGCCGT AATACCCG-3′). These primers allowed amplification of a 441-bp DNA fragment from *agr* group I, 575-bp fragment from *agr* group II, 323-bp fragment from *agr* group III, and 659-bp DNA fragment from *agr* group IV strains.

Statistical analysis {#Sec15}
--------------------

Comparison of categorical variables between study groups was performed with a chi-square test or with the Fisher exact test where appropriate, whereas differences among the numerical variables were analyzed by two-sample *t*-test. Multiple logistic regression analysis was applied to explore factors associated with treatment failure and 30-day mortality. Statistic significance was defined as a *P* value of \<0.05 in the tests. The statistics were performed using an SAS 9.3 for windows (SAS Institute, Inc., Cary, NC).
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